Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
14.30
+0.13 (0.92%)
At close: Oct 30, 2025, 4:00 PM EDT
14.40
+0.10 (0.70%)
After-hours: Oct 30, 2025, 5:49 PM EDT
Theravance Biopharma Employees
Theravance Biopharma had 97 employees as of December 31, 2024. The number of employees decreased by 2 or -2.02% compared to the previous year.
Employees
97
Change (1Y)
-2
Growth (1Y)
-2.02%
Revenue / Employee
$795,928
Profits / Employee
$134,340
Market Cap
720.17M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 97 | -2 | -2.02% |
| Dec 31, 2023 | 99 | -12 | -10.81% |
| Dec 31, 2022 | 111 | -48 | -30.19% |
| Dec 31, 2021 | 159 | -200 | -55.71% |
| Dec 31, 2020 | 359 | 43 | 13.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TBPH News
- 1 day ago - Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System - PRNewsWire
- 3 days ago - Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 - PRNewsWire
- 14 days ago - Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy - Business Wire
- 16 days ago - Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting - PRNewsWire
- 2 months ago - Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 2 months ago - Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy - PRNewsWire
- 2 months ago - Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire